| Next 10 |
Ad
NWBO News and Press Northwest Biotherapeutics Inc.
-
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 PR Newswire 78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md. , Jan. 6, 2023 /PRNewswire/ -...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Northwest Biotherapeutics (OTCMKTS: NWBO ) are in focus on Thursday. NWBO stock is up about 5% on the day and it’s got investors’ attention with a lawsuit against Citadel Securities, among other fi...
-
Trading data shows that seven preeminent market makers engaged in market manipulation via spoofing to drive down Northwest Biotherapeutics' stock prices as the company worked to raise funds to bring breakthrough cancer treatments to market NEW YORK, NY / ACCESSWIRE / December 1, 2022 / Today...
-
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma PR Newswire Both Median Survival and " Long Tail " of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results...
-
Summary Despite those excellent results, Northwest Biotherapeutics stock remains uninvestable. If the company behaved like a normal company, announced official data, published, filed for approval - sued its detractors - that would not have been the case. As it is, though...
-
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA PR Newswire PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/...
-
As is its wont, Northwest Biotherapeutics "progresses" at a snail's pace. NWBO stock is stagnant after that brief spurt in May. Among other problems, they have a fundamental problem with their cash runway. One more quarter, one more coverage of Northwest Bio ( OTCQB:NW...
-
CytoDyn Inc (OTCMKTS: CYDY) shares gained more than 8% closing the day at $0.73. CYDY has a market cap of over 524.8M$. CYDY is a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications. The company had announced the appointment o...
-
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility PR Newswire Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6,...
-
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program PR Newswire BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW ...
Stock Information
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Get NWBO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
